Intravenous Immunoglobulin Market to Grow with a CAGR of 7.01% through 2029

Expanding applications in autoimmune and neurological disorders is expected to drive the Global Intravenous Immunoglobulin Market growth in the forecast period, 2025-2029

According to TechSci Research report, “Intravenous Immunoglobulin Market – Global Industry Size, Share, Trends, Competition Forecast & Opportunities, 2029F”, the Global Intravenous Immunoglobulin Market stood at USD 11.76 billion in 2023 and is anticipated to grow with a CAGR of 7.01% in the forecast period through 2029. The global demographic shift toward an aging population is another significant driver fueling the demand for IVIG products. Elderly individuals are more susceptible to immunodeficiency disorders, autoimmune diseases, and neurological conditions due to age-related changes in immune function and increased incidence of chronic illnesses. As the elderly population continues to grow, the prevalence of these conditions is expected to rise, driving the need for IVIG therapy. Moreover, advancements in healthcare infrastructure and access to medical services in emerging economies are improving diagnosis rates and treatment outcomes for elderly patients, further driving market growth.

Advancements in biotechnology and manufacturing processes have played a pivotal role in driving the growth of the IVIG market. Innovations in plasma fractionation technologies have enabled the production of high-quality IVIG products with improved safety and efficacy profiles. Manufacturers are investing in research and development initiatives to enhance the purification and viral inactivation processes, ensuring the elimination of infectious agents and contaminants from IVIG preparations. Improvements in formulation techniques have led to the development of stabilized liquid IVIG formulations that offer convenience in storage and administration, further boosting market adoption. These technological advancements are driving efficiency gains in IVIG production, facilitating scalability, and meeting the growing demand for IVIG therapies worldwide.

Beyond immunodeficiency disorders, IVIG therapy is finding expanding applications in the treatment of autoimmune and neurological disorders. Autoimmune diseases such as immune thrombocytopenic purpura (ITP), Guillain-Barré syndrome (GBS), and myasthenia gravis (MG) are among the conditions benefiting from IVIG treatment. The ability of IVIG to modulate the immune response and mitigate autoimmune reactions has led to its widespread use in managing these conditions. Similarly, in neurological disorders like chronic inflammatory demyelinating polyneuropathy (CIDP) and multifocal motor neuropathy (MMN), IVIG has demonstrated efficacy in improving neuromuscular function and reducing disease progression.

Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "Global Intravenous Immunoglobulin Market”

The Global Intravenous Immunoglobulin Market is segmented into type, application, regional distribution, and company

Based on the application, the global intravenous immunoglobulin (IVIG) market is experiencing rapid growth, with the primary immunodeficiency diseases (PIDD) segment emerging as the fastest-growing application area. PIDD encompasses a group of inherited disorders characterized by defects in the immune system's ability to fight infections. As awareness about these conditions increases and diagnostic capabilities improve, more individuals are being diagnosed with PIDD, driving the demand for IVIG therapy. IVIG therapy involves administering immunoglobulin G (IgG) antibodies derived from pooled human plasma intravenously to patients with compromised immune systems. These antibodies help bolster the immune response, providing protection against infections.

North America leads the IVIG market, benefiting from its well-established healthcare infrastructure and presence of leading pharmaceutical and biotechnology companies specializing in IVIG production. These companies leverage advanced technology to develop high-quality IVIG products that meet stringent safety and efficacy standards. The growing prevalence of PIDD globally, coupled with advancements in medical diagnostics, is fueling the expansion of the IVIG market. Additionally, increasing research and development activities focused on developing novel IVIG formulations and expanding treatment indications are expected to further drive market growth. With rising awareness about immunodeficiency disorders and increasing access to healthcare services in emerging economies, the demand for IVIG therapy is projected to continue growing in the forecast period. However, challenges such as high treatment costs and regulatory hurdles may hinder market expansion to some extent.

Therefore, the IVIG market is poised for significant growth, driven by the increasing prevalence of primary immunodeficiency diseases and advancements in medical treatments and technologies. Key players in the market are focused on expanding their product portfolios, investing in research and development, and exploring new market opportunities to capitalize on this growth trajectory.

Major companies operating in Global Intravenous Immunoglobulin Market are:

• Bio Products Laboratory Ltd.
• Biotest AG
• China Biologic Products Holdings Inc.
• CSL Behring
• Grifols SA
• Kedrion SpA
• Shanghai RAAS Blood Products Co. Ltd
• Octapharma AG
• Takeda Pharmaceutical Company Limited
• Baxter International Inc

Download Free Sample Report

Customers can also request for 10% free customization on this report

“The global intravenous immunoglobulin (IVIG) market is witnessing significant growth driven by factors such as increasing prevalence of primary immunodeficiency diseases, advancements in medical diagnostics, and rising awareness about IVIG therapy. Primary immunodeficiency diseases, characterized by defects in the immune system, are contributing to the expanding demand for IVIG treatments. North America leads the market, benefiting from its well-established healthcare infrastructure, robust regulatory framework, and presence of leading pharmaceutical and biotechnology companies specializing in IVIG production. These companies leverage advanced technology to develop high-quality IVIG products that meet stringent safety and efficacy standards. With continuous research and development efforts and growing clinical trials, the IVIG market is poised for further expansion globally, catering to the increasing healthcare needs of patients with immunodeficiency disorders.” said Mr. Karan Chechi, Research Director, TechSci Research, a research-based management consulting firm.

“Intravenous Immunoglobulin Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type (IgG, IgA, IgM, IgE and IgD), By Application (Hypogammaglobulinemia, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Primary Immunodeficiency Diseases, Myasthenia Gravis, Multifocal Motor Neuropathy and Other Applications) Region and Competition, 2019-2029F”, has evaluated the future growth potential of Global Intravenous Immunoglobulin Market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Global Intravenous Immunoglobulin Market.

Contact

TechSci Research LLC

420 Lexington Avenue, Suite 300,

New York, United States- 10170

Tel: +1-332-258-6602

Email: [email protected]

Website: www.techsciresearch.com